Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03559569

Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease.

The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections.

The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Shock Cardiovascular Diseases Infection Infections Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Alexandra MONNIER

SUB_INVESTIGATOR

Catherine MUTTER

SUB_INVESTIGATOR

Christine KUMMERLEN

SUB_INVESTIGATOR

Dominique STEPHAN

SUB_INVESTIGATOR

Ferhat MEZIANI

CONTACT

[email protected]

03 69 55 10 24 ext. +33

Ferhat MEZIANI

PRINCIPAL_INVESTIGATOR

Hamid MERDJI

CONTACT

[email protected]

03 69 55 11 23 ext. +33

Hamid MERDJI

SUB_INVESTIGATOR

Hassène RAHMANI

SUB_INVESTIGATOR

Julie HELMS

SUB_INVESTIGATOR

Laure STIEL

SUB_INVESTIGATOR

Raphaël CLERE-JEHL

SUB_INVESTIGATOR

Sébastien GAERTNER

SUB_INVESTIGATOR

Xavier DELABRANCHE

SUB_INVESTIGATOR

Yannick RABOUEL

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Circulatory shock
  • patient with health care insurance

Exclusion criteria

  • Patients' refusal to participate in clinical research
  • Pregnant woman
  • Breastfeeding woman
  • A patient with a protective order

Treatment and study plan

Biological samples will be done to evaluate the endothelial and leukocyte senescence.

Biological

Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.

Primary outcomes

  1. The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells.

    Time frame: 1 year

    Biological samples will be done to evaluate the endothelial and leukocyte senescence.

Secondary outcomes

  1. Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states

    Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Madoé JULIANS

CONTACT

[email protected]

03 88 11 61 86 ext. +33

Morgane CLERC

CONTACT

[email protected]

03 88 11 68 55 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: Seneshock

Important dates

Study start
2019
Primary completion
2028
Study completion
2028
First posted
Jun 18, 2018
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.